Deferiprone: agranulocytosis and neurological disorders.
D000380:Agranulocytosis / Q000139:chemically induced*; D002614:Chelating Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D005602:France; D006801:Humans; D009422:Nervous System Diseases / Q000139:chemically induced*; D011728:Pyridones / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D017086:beta-Thalassemia / Q000188:drug therapy
D002614:Chelating Agents; D011728:Pyridones